Melanotan 1 vs Melanotan 2: Structure and Laboratory Evidence

Melanotan 1 (MT-1) and Melanotan 2 (MT-2) are structurally distinct analogues of alpha-melanocyte-stimulating hormone (α-MSH). MT-1 is a linear peptide containing 13 amino acids; MT-2 is a cyclic peptide containing seven amino acids. A nonclinical laboratory comparison should distinguish chemical identity, receptor activity, assay endpoints, and the experimental models underlying published evidence.

Neither peptide should be treated as an exclusively MC1R-selective probe. A pigment-related response alone does not identify the receptor responsible, establish activity in another model, or characterize a supplied research batch.

Structural differences between MT-1 and MT-2

Molecular features relevant to laboratory comparisons

Comparison point	Melanotan 1 / MT-1	Melanotan 2 / MT-2	Interpretation limit
Peptide architecture	Linear, 13-amino-acid peptide	Cyclic, seven-amino-acid peptide	Architecture alone does not establish potency or stability in an assay.
Defining modifications	Norleucine at position 4 and D-phenylalanine at position 7 of α-MSH	Shortened analogue with an internal lactam bridge	Sequence, stereochemistry, and cyclization are separate identity attributes. [1,2]
Naming	MT-1, NDP–α-MSH, and afamelanotide identify the underlying modified peptide in different contexts	MT-2 and Melanotan-II	A shared chemical name does not establish equivalence between preparations or formulations.
Receptor interpretation	Not an exclusively MC1R-selective probe	Not an exclusively MC1R-selective probe	Receptor attribution requires controls in the selected experimental system.
Comparative assay concentration	Calculate from the documented material identity and composition	Calculate from the documented material identity and composition	Equal peptide masses do not represent equal molar amounts.

MT-1: a modified full-length α-MSH analogue

MT-1 retains the 13-amino-acid length of α-MSH and incorporates norleucine and D-phenylalanine substitutions. NDP–α-MSH is a useful search term for the foundational chemical literature describing this identity. [1] Structural identity should remain separate from claims about activity, which require a specified model, endpoint, and experimental preparation.

MT-2: a shortened, ring-constrained analogue

MT-2 contains an internal lactam bridge that constrains its conformation. The cyclic-analogue development paper by Al-Obeidi and colleagues used molecular dynamics in its design approach; this is an in-silico component of the research, not a cell-based measurement. [2] A modeled conformation does not itself establish receptor selectivity, enzymatic stability, or functional activity.

The labels “1” and “2” do not indicate a performance ranking. Likewise, cyclic architecture is not evidence of a universal experimental advantage. Relative potency or persistence must be measured under defined, comparable conditions.

Receptor activity and selectivity answer different questions

MC1R is a member of the melanocortin receptor family and participates in pigment-related signaling in melanocytes. The receptor-cloning paper by Mountjoy and colleagues provides molecular-research context for this receptor family, rather than a matched MT-1-versus-MT-2 selectivity comparison. [8] Activity in pigment-producing cells cannot automatically be assigned to MC1R.

• Affinity describes ligand binding to a receptor under specified conditions.
• Potency describes the concentration associated with a defined response in an assay.
• Selectivity describes relative binding or functional activity across targets under comparable conditions.

A functional signaling assay and a binding assay measure different properties. Receptor expression, assay background, and receptor-specific controls affect interpretation. A strong response at one receptor does not demonstrate absence of activity at other receptor subtypes.

The related PT-141 versus Melanotan-II research article considers a different analogue comparison. It does not replace direct controls in an MT-1-versus-MT-2 experiment.

Interpret the literature by experimental model

In-vitro evidence: cultured human melanocytes

Abdel-Malek and colleagues studied normal human melanocytes in culture and reported melanogenic and mitogenic responses to melanotropic peptides. [7] These are in-vitro findings, not observations from people receiving a material. For cell-culture interpretation, total pigment and cell number should be considered separately: an increased total pigment measurement can reflect more cells, more pigment per cell, or both.

Hauser and colleagues studied cultured human melanocytes and reported that melanin content and MC1R function independently affected UVR-induced DNA damage in that in-vitro model. [10] The findings support distinguishing receptor function, pigment content, and DNA damage as measurements; they do not establish a comparative ranking of MT-1 and MT-2 or a protective property of either supplied material.

Animal evidence: pigmentation-pathway context

D'Orazio and colleagues investigated downstream pigmentation-pathway activation in a mouse model. [9] This animal study provides mechanistic context for the MC1R pathway, but it is not a direct MT-1-versus-MT-2 comparison. It does not characterize Alpha Carbon Labs materials or establish outcomes in humans.

Human evidence: distinct populations and preparations

The cited MT-1-related human literature includes a pigmentation study by Levine and colleagues and a study by Dorr and colleagues examining eumelanin and pigmentation endpoints in human participants. [4,5] These human studies are a separate evidence category from receptor assays and cultured-melanocyte experiments. They do not establish the identity or experimental performance of a laboratory preparation.

The cited MT-2 human literature includes Dorr and colleagues' small phase I pilot study. [3] Its human study population and early-stage design do not provide a matched nonclinical comparison with MT-1 or establish long-term safety.

Langendonk and colleagues studied afamelanotide in randomized clinical trials involving people with erythropoietic protoporphyria. [6] Those trials concern a defined clinical population and formulation, not Alpha Carbon Labs research materials. No formulation equivalence or product-specific conclusion follows from the shared peptide name.

The supplied references do not establish a definitive head-to-head ranking across laboratory models. Comparisons between separate publications must account for differences in biological systems, preparations, endpoints, controls, and measurement timing.

Match laboratory endpoints to the research question

The following are experimental design options, not assertions that either peptide has been validated in every listed model.

Assay options and their interpretation limits

Research question	Model or measurement	Interpretation limit
Does the material activate a defined receptor?	Cells expressing the receptor, with a signaling readout such as cAMP	Signaling does not by itself establish pigment accumulation or selectivity across receptors.
Does pigment content change?	Cultured melanocytes with melanin measurements and cell-number normalization	Total pigment does not identify pigment composition or receptor dependence.
Does pigment distribution change between cell types?	Melanocyte–keratinocyte coculture or reconstructed epidermis	These models do not reproduce all tissue or whole-organism processes.
Does a pigment change accompany a change in cellular damage?	Separate pigment and damage measurements in a validated model	Color change is not a substitute for a damage endpoint.

cAMP is an intracellular messenger used to assess an early signaling response; melanin accumulation is a later endpoint. Differences between these readouts need not be contradictory because they measure different stages of a pathway.

Eumelanin is a brown-black form of melanin. Neither visible sample color nor a total-melanin measurement necessarily determines eumelanin content. Pigment-composition conclusions require a method capable of distinguishing the relevant pigments.

Controls for a comparative experiment

• Specify the primary endpoint before comparing the peptides.
• Document receptor expression and relevant donor or cell-line characteristics.
• Match culture conditions, measurement timing, and vehicle controls.
• Compare documented molar concentrations rather than equal masses alone.
• Measure cell number and viability alongside pigment endpoints.
• Use receptor-specific controls before assigning a response to MC1R.
• Evaluate signaling, pigment composition, and cellular damage as separate outcomes.

Interpret apparent differences within the actual assay conditions. A pigment response alone does not establish reduced cellular damage, and an endpoint measured in one model cannot be assumed to apply to another.

Material identity, analytical documentation, and handling

Alpha Carbon Labs lists MT-1 and Melanotan-II as materials intended solely for nonclinical laboratory research. Publications concerning similarly named compounds do not establish the identity, purity, activity, or suitability of a supplied batch.

Review documentation for the intended sequence, molecular identity, stereochemistry, and linear or cyclic architecture. A purity percentage alone does not establish all of these attributes. Interpretation depends on the analytical method, what it can resolve, and the batch-specific results available.

The quality-control information and batch-specific certificates of analysis provide sources for reviewing available analytical documentation. The peptide-synthesis information offers related context for sequence and cyclization requirements. These resources should not be read as assertions that a batch meets an unstated specification or has demonstrated biological activity.

For laboratory handling, consult the applicable safety data sheet and documented storage and handling requirements, and follow the institution's chemical risk-assessment procedures. This comparison provides no batch-specific hazard classification or stability data; that absence should not be interpreted as evidence of low hazard.

Frequently asked research questions

Are MT-1, NDP–α-MSH, and afamelanotide interchangeable terms?

They identify the same underlying modified peptide in different naming contexts. They do not make preparations or formulations interchangeable. Chemical naming alone does not establish manufacturing characteristics, formulation composition, or product-specific evidence.

Is MT-2 simply a shorter MT-1?

No. MT-2 has a defining lactam ring as well as a shorter sequence. Sequence, stereochemistry, and cyclization all matter when defining the material and interpreting assay results.

Does a darker sample contain more eumelanin?

That conclusion requires a suitable composition measurement. Visible color, total melanin, and eumelanin content are distinct endpoints.

Which peptide is the better MC1R control?

Neither is automatically an MC1R-specific control. Choose a comparator based on the assay question and documented receptor activity, and establish receptor dependence using appropriate controls in the selected experimental system.

References

1. [1] Sawyer TK, Sanfilippo PJ, Hruby VJ, et al. [Nle4,D-Phe7]alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proceedings of the National Academy of Sciences USA. 1980;77(10):5754–5758. — https://doi.org/10.1073/pnas.77.10.5754
2. [2] Al-Obeidi F, Castrucci AML, Hadley ME, Hruby VJ. Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics. Journal of Medicinal Chemistry. 1989;32(12):2555–2561.
3. [3] Dorr RT, Lines R, Levine N, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences. 1996;58(20):1777–1784.
4. [4] Levine N, Sheftel SN, Eytan T, et al. Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin. JAMA. 1991;266(19):2730–2736.
5. [5] Dorr RT, Dvorakova K, Brooks C, et al. Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle4-D-Phe7]-alpha-MSH in humans. Photochemistry and Photobiology. 2004;79(5):473–477.
6. [6] Langendonk JG, Balwani M, Anderson KE, et al. Afamelanotide for Erythropoietic Protoporphyria. New England Journal of Medicine. 2015;373:48–59. — https://doi.org/10.1056/NEJMoa1411481
7. [7] Abdel-Malek Z, Swope VB, Suzuki I, et al. Mitogenic and melanogenic stimulation of normal human melanocytes by melanotropic peptides. Proceedings of the National Academy of Sciences USA. 1995;92(5):1789–1793. — https://doi.org/10.1073/pnas.92.5.1789
8. [8] Mountjoy KG, Robbins LS, Mortrud MT, Cone RD. The cloning of a family of genes that encode the melanocortin receptors. Science. 1992;257(5074):1248–1251.
9. [9] D'Orazio JA, Nobuhisa T, Cui R, et al. Topical drug rescue strategy and skin protection based on the role of Mc1r in UV-induced tanning. Nature. 2006;443:340–344.
10. [10] Hauser JE, Kadekaro AL, Kavanagh RJ, et al. Melanin content and MC1R function independently affect UVR-induced DNA damage in cultured human melanocytes. Pigment Cell Research. 2006;19(4):303–314.

Limitations: Published findings are specific to the models, populations, and preparations studied. They do not establish safety, effectiveness, approval, or suitability of material sold by Alpha Carbon Labs for human or veterinary use.